David Bautz

Joe Pantginis

Keith Markey

Michael Higgins

- Armata Pharmaceuticals' AP-SA02 demonstrated **significantly improved clinical outcomes** in its Phase 1b/2a "diSArm" study for complicated *Staphylococcus aureus* bacteremia, showing an **88% responder rate** (a **30 percentage point increase** over best available therapy alone) and **100% clinical response** at later timepoints, with **no serious adverse events related to the drug**.     
- The company completed its NCFB Phase 2 Tail wind Study for AP-PA02 in **Q3 2024**, which showed a **significant reduction in *P. aeruginosa* density** in treated subjects.    
- As of **June 30, 2025**, Armata Pharmaceuticals reported **$4.3 million** in unrestricted cash and cash equivalents, which does not include an additional **$15 million** received on **August 11, 2025**.

Armata Pharmaceuticals announces positive Phase 1b/2a clinical trial results for AP-SA02 and provides financial update

- **Insmed's BRINSUPRI (brensocatib) received FDA approval in August 2025**, becoming the **first-ever therapy** for non-cystic fibrosis bronchiectasis (NCFB) and the first drug targeting DPP1, addressing a market with high unmet medical needs.  **[921114_114f8a8a415b41418c18d8c77b7b319d_0]** **[921114_114f8a8a415b41418c18d8c77b7b319d_1]** 
- This approval is expected to significantly impact the NCFB market, which was valued at **USD 1.5 billion in 2024** across key geographies and is projected to grow at an **11.7% CAGR** in the US during 2020–2034.  **[921114_114f8a8a415b41418c18d8c77b7b319d_0]**  BRINSUPRI itself is anticipated to achieve peak sales of **~USD 5 billion**.  **[921114_114f8a8a415b41418c18d8c77b7b319d_2]** 
- The approval has intensified competition in the NCFB market, with other companies, including **Armata Pharmaceuticals**, also actively working on innovative NCFB drugs and advancing therapies like DPP1 inhibitors.  **[921114_114f8a8a415b41418c18d8c77b7b319d_0]** **[921114_114f8a8a415b41418c18d8c77b7b319d_2]** **[921114_114f8a8a415b41418c18d8c77b7b319d_3]**

Armata Pharmaceuticals (ARMP)